Advicenne SA
PAR:ALDVI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.13
2.071
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| FR |
|
Advicenne SA
PAR:ALDVI
|
25.6m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
276.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -17 526.7% |
| 30th Percentile | 1.3% |
| Median | 6.1% |
| 70th Percentile | 11.5% |
| Max | 89 700% |
Other Profitability Ratios
Advicenne SA
Glance View
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Nimes, Occitanie and currently employs 30 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Advicenne SA is -167.1%, which is above its 3-year median of -316%.
Over the last 3 years, Advicenne SA’s Operating Margin has increased from -325.4% to -167.1%. During this period, it reached a low of -432.1% on Dec 31, 2022 and a high of -167.1% on Jul 30, 2025.